Search results
Results from the WOW.Com Content Network
Phentermine is an norepinephrine and dopamine releasing agent (NDRA) and produces stimulant, rewarding, and appetite suppressant effects. [8] [9] [10] Chemically, it is a substituted amphetamine. [11] Phentermine was approved for medical use in the United States in 1959. [3] It is available as a generic medication. [3]
Phentermine and topiramate was developed by Vivus, a California pharmaceutical company. In December 2009, Vivus, Inc. submitted a new drug application (NDA) to the FDA and on 1 March 2010, Vivus, Inc. announced that the FDA accepted the NDA for review.
Phentermine (Adipex-P®, Lomaira®). Phentermine is a stimulant that suppresses appetite by affecting the central nervous system. ... GLP-1s mimic the action of glucagon-like peptide-1, a hormone ...
Phentermine is a substituted amphetamine and topiramate has an unknown mechanism of action Approved for weight management (short-term) by the FDA but not the European Medicines Agency [ 54 ] 10% [ 55 ] or 8.25 kilograms (18.2 lb) [ 56 ]
Amphetamine, the prototypical NDRA.. A norepinephrine–dopamine releasing agent (NDRA) is a type of drug which induces the release of norepinephrine (and epinephrine) and dopamine in the body and/or brain.
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.
A few facts for you according to the folks from The Anxiety and Depression Association of America and the National Institute of Mental Health: In 2020, an estimated 14.8 million U.S. adults aged ...
At the time of the 1990 decision, the FDA stated it "decided not to take action at that time, given the resources required to remove this authorization," as Red Dye No. 3 had already been approved ...